Phase II Study of Heme Arginate in Patients Planned for Cardiac Surgery
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
Price : $35 *
At a glance
- Drugs Haem arginate (Primary)
- Indications Acute kidney injury
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms HACS
- 31 Aug 2018 Biomarkers information updated
- 09 Dec 2015 Status changed from recruiting to completed according to United Kingdom Clinical Research Network record.
- 27 Nov 2015 Accrual to date is 105% according to United Kingdom Clinical Research Network record.